| Guidelines for the use of flow cytometry and cell sorting in immunological studies A Cossarizza, HD Chang, A Radbruch, A Acs, D Adam, S Adam‐Klages, ... European journal of immunology 49 (10), 1457-1973, 2019 | 1765 | 2019 |
| Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey R Zeiser, A Burchert, C Lengerke, M Verbeek, K Maas-Bauer, ... Leukemia 29 (10), 2062-2068, 2015 | 591 | 2015 |
| Longitudinal single-cell dynamics of chromatin accessibility and mitochondrial mutations in chronic lymphocytic leukemia mirror disease history L Penter, SH Gohil, C Lareau, LS Ludwig, EM Parry, T Huang, S Li, ... Cancer discovery 11 (12), 3048-3063, 2021 | 42 | 2021 |
| Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation L Penter, Y Zhang, A Savell, T Huang, N Cieri, EM Thrash, S Kim-Schulze, ... Blood, The Journal of the American Society of Hematology 137 (23), 3212-3217, 2021 | 33 | 2021 |
| FACS single cell index sorting is highly reliable and determines immune phenotypes of clonally expanded T cells. L Penter, K Dietze, L Bullinger, J Westermann, HP Rahn, L Hansmann European Journal of Immunology 48 (7), 1248-1250, 2018 | 33 | 2018 |
| Localization-associated immune phenotypes of clonally expanded tumor-infiltrating T cells and distribution of their target antigens in rectal cancer L Penter, K Dietze, J Ritter, MF Lammoglia Cobo, J Garmshausen, ... Oncoimmunology 8 (6), e1586409, 2019 | 29 | 2019 |
| Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease L Penter, Y Liu, JO Wolff, L Yang, L Taing, A Jhaveri, J Southard, M Patel, ... Blood 141 (15), 1817-1830, 2023 | 27 | 2023 |
| Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings JS Garcia, Y Flamand, L Penter, M Keng, BK Tomlinson, LM Mendez, ... Blood 141 (15), 1884-1888, 2023 | 26 | 2023 |
| Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancer G Oliveira, AM Egloff, AB Afeyan, JO Wolff, Z Zeng, RD Chernock, L Zhou, ... Science immunology 8 (87), eadf4968, 2023 | 21 | 2023 |
| Clonal expansion and interrelatedness of distinct B-lineage compartments in multiple myeloma bone marrow L Hansmann, A Han, L Penter, M Liedtke, MM Davis Cancer immunology research 5 (9), 744-754, 2017 | 20 | 2017 |
| Long-term follow-up of patients with corticosteroid-refractory graft-versus-host disease treated with ruxolitinib R Zeiser, A Burchert, C Lengerke, M Verbeek, K Maas-Bauer, S Metzelder, ... Blood 128 (22), 4561, 2016 | 19 | 2016 |
| A rapid screening system evaluates novel inhibitors of DNA methylation and suggests F-box proteins as potential therapeutic targets for high-risk neuroblastoma L Penter, B Maier, U Frede, B Hackner, T Carell, C Hagemeier, M Truss Targeted oncology 10, 523-533, 2015 | 18 | 2015 |
| In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities E Ten Hacken, T Sewastianik, S Yin, GB Hoffmann, M Gruber, K Clement, ... Blood cancer discovery 4 (2), 150-169, 2023 | 15 | 2023 |
| Improved T-cell immunity following neoadjuvant chemotherapy in ovarian cancer M Liu, N Tayob, L Penter, ML Sellars, A Tarren, V Chea, I Carulli, T Huang, ... Clinical Cancer Research 28 (15), 3356-3366, 2022 | 15 | 2022 |
| Natural barcodes for longitudinal single cell tracking of leukemic and immune cell dynamics L Penter, SH Gohil, CJ Wu Frontiers in Immunology 12, 788891, 2022 | 15 | 2022 |
| Safety and efficacy of decitabine plus ipilimumab in relapsed or refractory MDS/AML in the post-BMT or transplant naïve settings JS Garcia, Y Flamand, BK Tomlinson, M Keng, LM Mendez, S Khaled, ... Blood 136, 15-17, 2020 | 15 | 2020 |
| Coevolving JAK2V617F+ relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case L Penter, SH Gohil, T Huang, EM Thrash, D Schmidt, S Li, M Severgnini, ... Blood Advances 5 (22), 4701-4709, 2021 | 13 | 2021 |
| Personal tumor antigens in blood malignancies: genomics-directed identification and targeting L Penter, CJ Wu The Journal of Clinical Investigation 130 (4), 1595-1607, 2020 | 13 | 2020 |
| Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models L Penter, E Ten Hacken, J Southard, CA Lareau, LS Ludwig, S Li, ... Cancer research 83 (5), 667-672, 2023 | 9 | 2023 |
| Rapid single-cell identification of Epstein–Barr virus-specific T-cell receptors for cellular therapy MFL Cobo, C Welters, L Rosenberger, M Leisegang, K Dietze, C Pircher, ... Cytotherapy 24 (8), 818-826, 2022 | 9 | 2022 |
Donna NeubergDana-Farber Cancer InstituteVerified email at jimmy.harvard.edu
